Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
Sormani MP, Schiavetti I, Inglese M, Carmisciano L, Laroni A, Lapucci C, Visconti V, Serrati C, Gandoglia I, Tassinari T, Perego G, Brichetto G, Gazzola P, Mannironi A, Stromillo ML, Cordioli C, Landi D, Clerico M, Signoriello E, Cocco E, Frau J, Ferrò MT, Di Sapio A, Pasquali L, Ulivelli M, Marinelli F, Pizzorno M, Callari G, Iodice R, Liberatore G, Caleri F, Repice AM, Cordera S, Battaglia MA, Salvetti M, Franciotta D, Uccelli A; CovaXiMS study group. Sormani MP, et al. Among authors: gandoglia i. EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5. EBioMedicine. 2022. PMID: 35526306 Free PMC article.
Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Laroni A, et al. Among authors: gandoglia i. J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16. J Neuroimmune Pharmacol. 2012. PMID: 22585413
Teriflunomide treatment reduces B cells in patients with MS.
Gandoglia I, Ivaldi F, Laroni A, Benvenuto F, Solaro C, Mancardi G, Kerlero de Rosbo N, Uccelli A. Gandoglia I, et al. Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e403. doi: 10.1212/NXI.0000000000000403. eCollection 2017 Nov. Neurol Neuroimmunol Neuroinflamm. 2017. PMID: 29082295 Free PMC article.
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: gandoglia i. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M. De Mercanti SF, et al. Among authors: gandoglia i. J Neurol Sci. 2021 May 15;424:117385. doi: 10.1016/j.jns.2021.117385. Epub 2021 Mar 6. J Neurol Sci. 2021. PMID: 33770708
19 results